The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
The Hsp90 chaperone complex as a novel target for cancer therapy
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · cited 1×
“Her-2 (p185) is a receptor tyrosine kinase overexpressed in a significant proportion of malignancies, including breast, ovarian, prostate and gastric cancers, and is associated with a poor prognosis [32, 33].”
BackgroundSlamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“In the case of trastuzamab, a multicenter phase III trial recently reported that in patients with metastatic erbB2-expressing breast cancer, trastuzamab in combination with chemotherapy is more effective than trastuzamab alone (median survival 25.1 versus 20.3 months) [ 5 ].”
BackgroundInfluentialMolecular Chaperones in the Cytosol: from Nascent Chain to Folded Protein
Hartl, F. U., & Hayer-Hartl, M. (2002) · Science · doi:10.1126/science.1068408 · Cited by 3,347
Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
A new puffing pattern induced by temperature shock and DNP in drosophila
Ritossa, F. (1962) · Experientia · doi:10.1007/bf02172188 · Cited by 2,068
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Steroid Receptor Interactions with Heat Shock Protein and Immunophilin Chaperones*
Pratt, W. B., & Toft, D. O. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.3.0303 · Cited by 1,791
Self-citationIn vivo amplification of the androgen receptor gene and progression of human prostate cancer
Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., & Kallioniemi, O.-P. (1995) · Nature Genetics · doi:10.1038/ng0495-401 · Cited by 1,484 · cited 1×
“The progression of human prostate cancer is often linked to a high level of androgen receptor expression or mutations [75–77].”
BackgroundPratt, W. B., & Toft, D. O. (2003) · Experimental Biology and Medicine · doi:10.1177/153537020322800201 · Cited by 1,483
Self-citationWhitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., & Neckers, L. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8324 · Cited by 1,444
Stebbins, C. E., Russo, A. A., Schneider, C., Rosen, N., Hartl, F. U., & Pavletich, N. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80203-2 · Cited by 1,364
Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene Products
Lugo, T. G., Pendergast, A.-M., Muller, A. J., & Witte, O. N. (1990) · Science · doi:10.1126/science.2408149 · Cited by 1,281
Prodromou, C., Roe, S. M., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1997) · Cell · doi:10.1016/s0092-8674(00)80314-1 · Cited by 1,265
Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer
Taplin, M.-E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., & Balk, S. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505253322101 · Cited by 1,253
Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology
Semenza, G. L. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02090-1 · Cited by 930
Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)
Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 882
Imatinib Mesylate — A New Oral Targeted Therapy
Savage, D. G., & Antman, K. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmra013339 · Cited by 844
Heisterkamp, N., Stephenson, J. R., Groffen, J., Hansen, P. F., de Klein, A., Bartram, C. R., & Grosveld, G. (1983) · Nature · doi:10.1038/306239a0 · Cited by 842
Blocking Oncogenic Ras Signaling for Cancer Therapy
Adjei, A. A. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.14.1062 · Cited by 831
Young, J. C., Moarefi, I., & Hartl, F. U. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.200104079 · Cited by 822
Development of Matrix Metalloproteinase Inhibitors in Cancer Therapy
Hidalgo, M., & Eckhardt, S. G. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.3.178 · Cited by 798
Bartram, C. R., de Klein, A., Hagemeijer, A., van Agthoven, T., van Kessel, A. G., Bootsma, D., Grosveld, G., Ferguson-Smith, M. A., Davies, T., Stone, M., et al. (1983) · Nature · doi:10.1038/306277a0 · Cited by 747
Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1α-degradative pathway
Isaacs, J. S., Jung, Y.-J., Mimnaugh, E. G., Martinez, A., Cuttitta, F., & Neckers, L. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204733200 · Cited by 663 · cited 1×
“Treatment with GA prevents heat and hypoxia-induced HIF-1α expression [56], and in renal cell carcinoma cell lines, promotes HIF-1α ubiquitination and proteasomemediated degradation independent of the von Hippel–Lindau tumor suppressor gene [57].”
BackgroundBasso, A. D., Solit, D. B., Chiosis, G., Giri, B., Tsichlis, P., & Rosen, N. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206322200 · Cited by 628
Hsp90: Chaperoning signal transduction
Richter, K., & Buchner, J. (2001) · Journal of Cellular Physiology · doi:10.1002/jcp.1131 · Cited by 570
Grenert, J. P., Sullivan, W. P., Fadden, P., Haystead, T. A. J., Clark, J., Mimnaugh, E., Krutzsch, H., Ochel, H.-J., Schulte, T. W., Sausville, E., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.38.23843 · Cited by 569
Self-citationSteroid receptors and their associated proteins
Smith, D. F. (1993) · Molecular Endocrinology · doi:10.1210/me.7.1.4 · Cited by 545
Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent
Supko, J. G., Hickman, R. L., Grever, M. R., & Malspeis, L. (1995) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00689048 · Cited by 510
Marcu, M. G., Chadli, A., Bouhouche, I., Catelli, M., & Neckers, L. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003701200 · Cited by 502
Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4
Stepanova, L., Leng, X., Parker, S. B., & Harper, J. W. (1996) · Genes & Development · doi:10.1101/gad.10.12.1491 · Cited by 483 · cited 2×
“Pharmacological disruption of Hsp90 with BA results in loss of association of Cdc37 with Cdk4, resulting in a reduction in the half-life of newly synthesized Cdk4 [41].”
Backgroundp53 in growth control and neoplasia
Gottlieb, T. M., & Oren, M. (1996) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(95)00019-c · Cited by 481
The heat-shock response: regulation and function of heat-shock proteins and molecular chaperones.
Morimoto, R. I., Kline, M. P., Bimston, D. N., & Cotto, J. J. (1997) · PubMed · Cited by 435
Solit, D. B., Zheng, F. F., Drobnjak, M., Münster, P. N., Higgins, B., Verbel, D., Heller, G., Tong, W. P., Cordon‐Cardo, C., Agus, D. B., et al. (2002) · PubMed · Cited by 433
O'Connell, M. J., Laurie, J. A., Kahn, M., Fitzgibbons, R. J., Erlichman, C., Shepherd, L., Moertel, C. G., Kocha, W. I., Pazdur, R., Wieand, H. S., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.295 · Cited by 417
Self-citationNovobiocin and Related Coumarins and Depletion of Heat Shock Protein 90-Dependent Signaling Proteins
Marcu, M. G., Schulte, T. W., & Neckers, L. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.242 · Cited by 405
Schulte, T. W., Akinaga, S., Soga, S., Sullivan, W., Stensgard, B., Toft, D., & Neckers, L. M. (1998) · Cell Stress & Chaperones · doi:10.1379/1466-1268(1998)003<0100:arbttn>2.3.co;2 · Cited by 403
Self-citationKelland, L. R., Sharp, S. Y., Rogers, P. M., Myers, T. G., & Workman, P. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.22.1940 · Cited by 350
Hypoxia‐induced activation of HIF‐1: role of HIF‐1α‐Hsp90 interaction
Minet, E., Mottet, D., Michel, G., Roland, I., Raes, M., Remacle, J., & Michiels, C. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01359-9 · Cited by 324
Hostein, I., Robertson, D. M., Di-Stefano, F., Workman, P., & Clarke, P. A. (2001) · PubMed · Cited by 320
Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90.
Blagosklonny, M. V., Toretsky, J., Bohen, S., & Neckers, L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8379 · Cited by 314
Progesterone Receptor Structure and Function Altered by Geldanamycin, an hsp90-Binding Agent
Smith, D. F., Whitesell, L., Nair, S. C., Chen, S., Prapapanich, V., & Rimerman, R. A. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.12.6804 · Cited by 289
Chiosis, G., Timaul, M. N., Lucas, B., Munster, P. N., Zheng, F. F., Sepp-Lorenzino, L., & Rosen, N. (2001) · Chemistry & Biology · doi:10.1016/s1074-5521(01)00015-1 · Cited by 288
Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol
Sharma, S. V., Agatsuma, T., & Nakano, H. (1998) · Oncogene · doi:10.1038/sj.onc.1201790 · Cited by 277
Westbrook, C., Hooberman, A., Spino, C., Dodge, R., Larson, R., Davey, F., Wurster- Hill, D., Sobol, R., Schiffer, C., & Bloomfield, C. (1992) · Blood · doi:10.1182/blood.v80.12.2983.2983 · Cited by 274
Schulte, T. W., Blagosklonny, M. V., Romanova, L., Mushinski, J. F., Monia, B. P., Johnston, J. F., Nguyen, P., Trepel, J., & Neckers, L. M. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5839 · Cited by 269
Basso, A. D., Solit, D. B., Munster, P. N., & Rosen, N. (2002) · Oncogene · doi:10.1038/sj.onc.1205184 · Cited by 265
Nimmanapalli, R., O’Bryan, E., & Bhalla, K. N. (2001) · PubMed · Cited by 242
Uehara, Y., Hori, M., Takeuchi, T., & Umezawa, H. (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.6.2198 · Cited by 233
A Nucleotide-dependent Molecular Switch Controls ATP Binding at the C-terminal Domain of Hsp90
Söti, C., Rácz, A., & Csermely, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m105568200 · Cited by 212
Gelmon, K. A., Eisenhauer, E. A., Harris, A. L., Ratain, M. J., & Workman, P. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.15.1281 · Cited by 204
Geldanamycin selectively destabilizes and conformationally alters mutated p53.
Blagosklonny, M. V., Toretsky, J. A., & Neckers, L. (1995) · PubMed · Cited by 202
Stancato, L. F., Silverstein, A. M., Owens-Grillo, J. K., Chow, Y.-H., Jove, R., & Pratt, W. B. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4013 · Cited by 200
Schnur, R. C., Corman, M. L., Gallaschun, R. J., Cooper, B. A., Dee, M. F., Doty, J. L., Muzzi, M. L., Moyer, J. D., & DiOrio, C. I. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00019a010 · Cited by 199
Conventional cancer therapy: promise broken or promise delayed?
Tannock, I. F. (1998) · The Lancet · doi:10.1016/s0140-6736(98)90327-0 · Cited by 191
The nuclear phosphoinositide 3-kinase/AKT pathway: a new second messenger system
Neri, L. M., Borgatti, P., Capitani, S., & Martelli, A. M. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(02)00300-1 · Cited by 184
Katschinski, D. M., Le, L., Heinrich, D., Wagner, K. F., Höfer, T., Schindler, S., & Wenger, R. H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110377200 · Cited by 184
Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition.
Whitesell, L. J., Shifrin, S. D., Schwab, G., & Neckers, L. M. (1992) · PubMed · Cited by 176
Münster, P. N., Basso, A., Solit, D., Norton, L., & Rosen, N. (2001) · PubMed · Cited by 173
Binding of ATP to Heat Shock Protein 90
Garnier, C., Lafitte, D., Tsvetkov, P. O., Barbier, P., Leclerc, J., Millot, J., Briand, C. M., Makarov, A. А., CATELLI, M. G., & Peyrot, V. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111874200 · Cited by 166
HSP40 Binding Is the First Step in the HSP90 Chaperoning Pathway for the Progesterone Receptor
Hernández, M. P., Chadli, A., & Toft, D. O. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111445200 · Cited by 144
Self-citationInhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest.
Srethapakdi, M., Liu, F., Tavorath, R., & Rosen, N. X. (2000) · PubMed · Cited by 136
Egorin, M. J., Rosen, D. M., Wolff, J., Callery, P. S., Musser, S. M., & Eiseman, J. L. (1998) · PubMed · Cited by 133
Small molecule modulators of cyclin-dependent kinases for cancer therapy
Senderowicz, A. M. (2000) · Oncogene · doi:10.1038/sj.onc.1204085 · Cited by 132
Effect of geldanamycin on androgen receptor function and stability
Vanaja, D. K., Mitchell, S. H., Toft, D. O., & Young, C. Y. F. (2002) · Cell Stress and Chaperones · doi:10.1379/1466-1268(2002)007<0055:eogoar>2.0.co;2 · Cited by 130
Self-citationStevenson, J. P., Yao, K.-S., Gallagher, M., Friedland, D. P., Mitchell, E. P., Cassella, A., Monia, B. P., Kwoh, T. J., Yu, R. Z., Holmlund, J., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2227 · Cited by 129
Bagatell, R., Khan, O., Paine-Murrieta, G. D., Taylor, C. W., Akinaga, S., & Whitesell, L. J. (2001) · PubMed · Cited by 118
Depletion of the erbB-2 gene product p185 by benzoquinoid ansamycins.
Miller, P. E., DiOrio, C., Moyer, M. P., Schnur, R. C., Bruskin, A. M., Cullen, W., & Moyer, J. D. (1994) · PubMed · Cited by 113
An, W. G., Schnur, R. C., Neckers, L., & Blagosklonny, M. V. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050626 · Cited by 104
Deplanque, G., & Harris, A. L. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00149-0 · Cited by 95
Hsp90, not Grp94, regulates the intracellular trafficking and stability of nascent ErbB2
Xu, W., Mimnaugh, E. G., Kim, J.-S., Trepel, J. B., & Neckers, L. Μ. (2002) · Cell Stress and Chaperones · doi:10.1379/1466-1268(2002)007<0091:hngrti>2.0.co;2 · Cited by 79
Repression of Dioxin Signal Transduction in Fibroblasts
Gradin, K., Toftgård, R., Poellinger, L., & Berghard, A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.19.13511 · Cited by 74
The Benzoquinone Ansamycin Geldanamycin Stimulates Proteolytic Degradation of Focal Adhesion Kinase
Ochel, H.-J., Schulte, T. W., Nguyen, P., Trepel, J. B., & Neckers, L. (1999) · Molecular Genetics and Metabolism · doi:10.1006/mgme.1998.2774 · Cited by 72
The Raf-1 serine/threonine protein kinase.
Magnuson, N. S., Beck, T. W., Vahidi, H., et al. (1994) · PubMed · Cited by 67
Prostate cancer schemes for androgen escape
Brinkmann, A. O., & Trapman, J. (2000) · Nature Medicine · doi:10.1038/76194 · Cited by 60
Mandler, R. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.19.1573 · Cited by 53
Hartmann, F., Horak, E. M., Cho-Phan, C. D., Lupu, R., Bolen, J. B., Stetler-Stevenson, M. A., Pfreundschuh, M. G., Waldmann, T. A., & Horak, I. D. (1997) · International Journal of Cancer · Cited by 46
LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family
Chiosis, G., Rosen, N. X., & Sepp‐Lorenzino, L. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00099-3 · Cited by 46
Cited by
Physical stimuli-responsive polymeric micelles for anti-cancer drug delivery
Rapoport, N. (2007) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2007.05.009 · Cited by 1,002
Hsp70 and Hsp90—a relay team for protein folding
Wegele, H., Müller, L., & Buchner, J. (2004) · Reviews of Physiology, Biochemistry and Pharmacology · doi:10.1007/s10254-003-0021-1 · Cited by 605
Marzec, M., Eletto, D., & Argon, Y. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.10.013 · Cited by 390
Heat shock protein 90: The cancer chaperone
Neckers, L. (2007) · Journal of Biosciences · doi:10.1007/s12038-007-0051-y · Cited by 365
Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients With Advanced Cancer
Goetz, M. P., Toft, D., Reid, J., Ames, M., Stensgard, B., Safgren, S., Adjei, A. A., Sloan, J., Atherton, P., Vasile, V., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.119 · Cited by 336
Self-citation
Metadata
- Authors
- Goetz, M. P., Toft, D. O., Ames, M. M., & Erlichman, C.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2003-08
- Volume
- 14
- Issue
- 8
- Pages
- 1169-1176
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2162423163
- Cited by
- 334
- References
- 77
- FWCI
- 8.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.